Kyverna Taps Greg Martini as CFO with 325,000-Share Option Grant
Kyverna Therapeutics appointed veteran biopharma executive Greg Martini as CFO effective May 18, 2026, replacing Dr. Marc Grasso to oversee financial strategy, capital allocation and investor relations during commercialization of miv-cel. Martini received an option grant for 325,000 shares vesting over four years under the Nasdaq-compliant inducement plan.
1. Appointment and Role
Kyverna Therapeutics named Greg Martini as Chief Financial Officer effective May 18, 2026, succeeding Dr. Marc Grasso in a consulting role to ensure seamless transition. Martini will direct corporate finance, capital allocation, treasury operations and investor relations as the company prepares to commercialize miv-cel in stiff person syndrome.
2. Inducement Option Grant
On his start date, Kyverna granted Martini an option to purchase 325,000 shares of common stock under the 2024 Inducement Equity Incentive Plan, priced at the closing share price on May 18, 2026. The options vest over four years with 25% vesting after one year and the remainder vesting monthly, subject to continued service.
3. Financial Leadership Background
Martini joins from Ironwood Pharmaceuticals where he served as Senior Vice President and CFO, leading commercial expansion of LINZESS® and achieving positive EBITDA and cash flow. His earlier roles include strategic finance at Ironwood, corporate development at Thermo Fisher Scientific, and positions with Ernst & Young and Raytheon Technologies.